Le Lézard
Classified in: Health, Business
Subjects: ACC, SRP

QIAGEN Announces Details for Completion of Approximately $250 Million Synthetic Share Repurchase


VENLO, The Netherlands, January 18, 2017 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) (the "Company") today announced details for completion of a synthetic share repurchase plan that combines a direct capital repayment with a reverse stock split. The capital repayment forms part of a commitment announced in July 2016 to return $300 million to shareholders by the end of 2017.

The synthetic share repurchase, which was announced in August 2016 and approved in October 2016 at an Extraordinary General Meeting of Shareholders, involves an approach used by various large, multinational Dutch companies as an efficient way to provide returns to all shareholders, and to do so in a faster and more efficient way than through a traditional open-market share repurchase program. Following the receipt of shareholder approval for the transaction, the Company observed a two-month creditor objection period as required under Dutch law.

The terms of the synthetic share repurchase are as follows: every 27 issued QIAGEN shares will be consolidated into 26 QIAGEN shares and following the implementation of the consolidation, the Company will issue to its shareholders a capital repayment of $1.04 per pre-split share held by each shareholder (which is equivalent to ?0.9752 (*) per pre-split share based on today's ECB foreign exchange reference rate).

Click here for full press release

https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID={5BB7AC57-4951-4CF9-BB63-0766EA72D425}&lang=en

Contacts:

QIAGEN

Investor Relations
John Gilardi
+49-2103-29-11711
e-mail: [email protected]

Public Relations
Dr. Thomas Theuringer
+49-2103-29-11826
e-mail: [email protected]


SOURCE QIAGEN N.V.


These press releases may also interest you

at 01:00
April 29, 2024 First-quarter highlights Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4%Comparable order intake -3.8%, mainly due to ChinaUSD 1.1 billion Respironics litigation settlement reached in the US...

at 00:45
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of ?15 million in its second closing with participation from...

at 00:20
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx. PPI...

at 00:00
Building on its commitment to identify strengths and gaps in the R&D pipeline for antivirals, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral treatments to help protect the world ahead...

at 00:00
Spectrum Dynamic's customers will...

28 avr 2024
AriBio Co., Ltd. (AriBio) announced authorisation from the European Medicines Agency (EMA) for POLARIS-AD (AR1001-ADP3-US01), a global, phase 3, early Alzheimer's disease clinical trial. EMA now aligns with the U.S. Food and Drug Administration (FDA)...



News published on and distributed by: